Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination

Rheumatology (Oxford). 2021 Jul 1;60(7):e225-e226. doi: 10.1093/rheumatology/keaa880.

Authors

Rebecca H Haberman¹, Rochelle Castillo¹, Jose U Scher¹

Affiliation

¹ Department of Medicine, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA.

PMID: 33369644
DOI: 10.1093/rheumatology/keaa880

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adalimumab / therapeutic use*
Adult
Antirheumatic Agents / therapeutic use*
Arthritis, Psoriatic / complications
Arthritis, Psoriatic / drug therapy*
Biological Products / therapeutic use
Dermatologic Agents / therapeutic use*
Drug Therapy, Combination
Female
Humans
Psoriasis / complications
Psoriasis / drug therapy*
Psoriasis / pathology
Remission Induction
Severity of Illness Index
Ustekinumab / therapeutic use*

Substances

Antirheumatic Agents
Biological Products
Dermatologic Agents
Ustekinumab
Adalimumab